Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors.
作者信息
Dolcetti Riccardo, López-Soto Alejandro, Dal Col Jessica
机构信息
The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia.
Departamento de Biología Funcional, Inmunología, Universidad de Oviedo, Oviedo, Spain.
出版信息
Front Immunol. 2020 Mar 31;11:507. doi: 10.3389/fimmu.2020.00507. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors.社论：实体瘤和血液肿瘤中基于树突状细胞的免疫疗法
Front Immunol. 2020 Mar 31;11:507. doi: 10.3389/fimmu.2020.00507. eCollection 2020.
2
Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?直接树突状细胞接种免疫：一个旧观念的新纪元？
Front Immunol. 2019 Sep 25;10:2303. doi: 10.3389/fimmu.2019.02303. eCollection 2019.
3
Dendritic cells in tumor immunology and immunotherapy.肿瘤免疫学与免疫治疗中的树突状细胞
Curr Drug Targets. 2004 Jan;5(1):17-39. doi: 10.2174/1389450043490640.
4
Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy.调节性 T 细胞清除 cDC1 细胞会危及癌症免疫治疗。
Oncoimmunology. 2024 Oct 4;13(1):2412874. doi: 10.1080/2162402X.2024.2412874. eCollection 2024.
5
A Novel Dendritic Cell-Based Vaccination Protocol to Stimulate Immunosurveillance of Aggressive Cancers.一种基于树突状细胞的新型疫苗接种方案，用于刺激侵袭性癌症的免疫监视。
Methods Mol Biol. 2019;1884:317-333. doi: 10.1007/978-1-4939-8885-3_22.
6
Immunotherapy using dendritic cells picks up steam.使用树突状细胞的免疫疗法渐趋流行。
J Natl Cancer Inst. 1997 Apr 16;89(8):541-2. doi: 10.1093/jnci/89.8.541.
7
[Effects of Immune Checkpoint Inhibitor Combined with Dendritic Cell Therapy and Hyperthermia].免疫检查点抑制剂联合树突状细胞疗法及热疗的效果
Gan To Kagaku Ryoho. 2018 Oct;45(10):1472-1474.
8
Tumor-dendritic cell fusion technology and immunotherapy strategies.肿瘤-树突状细胞融合技术与免疫治疗策略
J Immunother. 2001 Mar-Apr;24(2):99-100.
9
Immunotherapy and Vaccine Development.免疫疗法与疫苗研发
J Immunol Res. 2018 Jun 13;2018:8751027. doi: 10.1155/2018/8751027. eCollection 2018.
10
Dendritic cell vaccination and other strategies to tip the balance of the immune system : DC2007 5th International Meeting, July 16-18, Bamberg, Germany.树突状细胞疫苗接种及其他调节免疫系统平衡的策略：DC2007第五届国际会议，7月16 - 18日，德国班贝格
Cancer Immunol Immunother. 2008 Jun;57(6):913-28. doi: 10.1007/s00262-007-0443-8. Epub 2008 Jan 31.
引用本文的文献
1
PEG Spacer Length Substantially Affects Antibody-Based Nanocarrier Targeting of Dendritic Cell Subsets.聚乙二醇间隔物长度对基于抗体的纳米载体靶向树突状细胞亚群有显著影响。
Pharmaceutics. 2022 Aug 2;14(8):1614. doi: 10.3390/pharmaceutics14081614.
2
Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.治疗性脂质体疫苗用于树突状细胞的激活或耐受。
Front Immunol. 2021 May 13;12:674048. doi: 10.3389/fimmu.2021.674048. eCollection 2021.
3
Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors.利用佐剂 TLR4 结合 60S 酸性核糖体蛋白 P2 和免疫检查点抑制剂改善基于树突状细胞的疫苗。
Cancer Immunol Immunother. 2021 Apr;70(4):1075-1088. doi: 10.1007/s00262-020-02759-6. Epub 2020 Oct 28.
本文引用的文献
1
Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.CD47 表达增强与 NSCLC 中酪氨酸激酶抑制剂吉非替尼的脱靶耐药相关。
Front Immunol. 2020 Jan 31;10:3135. doi: 10.3389/fimmu.2019.03135. eCollection 2019.
2
Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment.治疗性癌症疫苗单独或与免疫检查点抑制剂联合用于癌症治疗的安全性和有效性。
Front Pharmacol. 2019 Oct 11;10:1184. doi: 10.3389/fphar.2019.01184. eCollection 2019.
3
Regulation of lung immunity by dendritic cells: Implications for asthma, chronic obstructive pulmonary disease and infectious disease.树突状细胞对肺部免疫的调节：在哮喘、慢性阻塞性肺疾病和传染病中的意义。
Innate Immun. 2019 Aug;25(6):326-336. doi: 10.1177/1753425918821732.
4
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.系统性临床肿瘤消退和原位疫苗接种增强 PD1 阻断作用。
Nat Med. 2019 May;25(5):814-824. doi: 10.1038/s41591-019-0410-x. Epub 2019 Apr 8.
5
Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.治疗性癌症疫苗与抗血管生成疗法和免疫检查点阻断联合应用。
Front Immunol. 2019 Mar 14;10:467. doi: 10.3389/fimmu.2019.00467. eCollection 2019.
6
In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy.原位树突状细胞疫苗用于有效的癌症免疫治疗。
ACS Nano. 2019 Mar 26;13(3):3083-3094. doi: 10.1021/acsnano.8b08346. Epub 2019 Mar 7.
7
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.成功的抗 PD-1 癌症免疫疗法需要涉及细胞因子 IFN-γ 和 IL-12 的 T 细胞-树突状细胞串扰。
Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11.
8
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.自然杀伤细胞-树突状细胞轴定义了检查点治疗反应性肿瘤微环境。
Nat Med. 2018 Aug;24(8):1178-1191. doi: 10.1038/s41591-018-0085-8. Epub 2018 Jun 25.
9
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.自然杀伤细胞刺激 cDC1 细胞向肿瘤微环境募集，促进癌症免疫控制。
Cell. 2018 Feb 22;172(5):1022-1037.e14. doi: 10.1016/j.cell.2018.01.004. Epub 2018 Feb 8.
10
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.免疫原性抗原的密度并不能解释黑色素瘤中T细胞炎症性肿瘤微环境的存在与否。
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. doi: 10.1073/pnas.1609376113. Epub 2016 Nov 11.
Zotero 插件